FY2024 Earnings Forecast for GANX Issued By Chardan Capital

Gain Therapeutics, Inc. (NASDAQ:GANX) – Equities researchers at Chardan Capital boosted their FY2024 EPS estimates for shares of Gain Therapeutics in a research note issued to investors on Tuesday, November 19th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings of ($0.99) per share for the year, up from their prior forecast of ($1.01). Chardan Capital currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.05) per share. Chardan Capital also issued estimates for Gain Therapeutics’ FY2025 earnings at ($0.74) EPS.

A number of other research analysts also recently issued reports on the stock. Oppenheimer reiterated an “outperform” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Wednesday, October 9th.

Gain Therapeutics Stock Up 6.2 %

Gain Therapeutics stock opened at $1.72 on Friday. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a 12-month low of $0.89 and a 12-month high of $5.33. The firm’s fifty day moving average is $2.06 and its 200 day moving average is $1.74. The company has a market capitalization of $45.61 million, a PE ratio of -1.56 and a beta of 0.33.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in Gain Therapeutics by 48.0% during the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after buying an additional 88,236 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after purchasing an additional 72,000 shares in the last quarter. Warberg Asset Management LLC bought a new position in shares of Gain Therapeutics during the second quarter valued at about $66,000. Finally, Hohimer Wealth Management LLC bought a new position in shares of Gain Therapeutics during the second quarter valued at about $422,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.